United Spirits' analyst price target has been revised upward from ₹1,559.04 to ₹1,601.50. Analysts cite modest adjustments in growth and profitability assumptions to support this increase.
What's in the News
- United Spirits places the Royal Challengers Bengaluru (RCB) cricket team under strategic review, considering multiple alternatives including a potential sale, as the company focuses on its core alcohol beverage business (company exchange filing).
- Mint reports that Adar Poonawalla, owner of Serum Institute, is in talks to acquire the entire RCB franchise for a valuation of up to $1.2 billion. Diageo India declined to comment (Mint, CNBC TV-18).
- United Spirits declares a final dividend of INR 8 per equity share for the financial year ending 31 March 2025, as approved at the recent AGM (company announcement).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from ₹1,559.04 to ₹1,601.50.
- Discount Rate increased marginally from 12.73% to 12.76%.
- Revenue Growth forecast has fallen slightly from 9.31% to 9.25%.
- Net Profit Margin estimate decreased from 15.73% to 15.53%.
- Future P/E multiple forecast has risen from 61.05x to 63.87x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.